Home Neoplasma 2018 Neoplasma Vol.65, No.6, p.965-971, 2018

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.6, p.965-971, 2018

Title: Uveal melanoma survival rates after single dose stereotactic radiosurgery
Author: A. Furdova, P. Babal, D. Kobzova, P. Zahorjanova, K. Kapitanova, M. Sramka, G. Kralik, R. Furda, V. Krasnik

Abstract: This paper presents the long-term results of single dose stereotactic radiosurgery for intraocular uveal malignant melanoma, and summarizes the results of the retrospective study in 170 Slovak patients. A group of uveal melanoma patients (149 choroidal melanoma, 21 ciliary body melanoma) from 20 to 92 years of age with 59 year median were treated in 2001–2016. There were 81males (47.7%) and 89 females 89 (52.3%). The median overall follow-up time was three years. The median tumor volume at baseline was 0.5 cm3 (ranging from 0.2 to 1.6 cm3). The therapeutic dose was 35.0 Gy by 99% of dose volume histogram. The survival after single dose stereotactic radiosurgery was 96% in one year, 93% in two years,
84% in five years, 80% in seven years and 52% in eleven years. Secondary enucleation was necessary for 22 patients because of secondary glaucoma complication. The enucleation free interval ranged from one to six years. The survival rates in five year intervals and necessity of secondary enucleation due to complications after single dose stereotactic radiosurgery is comparable to other techniques.

Keywords: uveal melanoma, linear accelerator, stereotactic radiosurgery, survival, intraocular tumor
Published online: 08-Oct-2018
Year: 2018, Volume: 65, Issue: 6 Page From: 965, Page To: 971

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.